Introduction: Leukemia and other lymphoid and hematopoietic malignancies exhibit high prevalence and mortality among indigenous populations in the Amazon, reflecting diagnostic and therapeutic challenges in isolated, resource-limited regions. Regional studies report age-standardized incidence and mortality ratios exceeding those of non-indigenous groups, suggesting genetic, socioeconomic, and geographic influences on disease dynamics. Objectives: To analyze the epidemiological profile of mortality from lymphoid, hematopoietic, and related malignant neoplasms in the indigenous population of Pará State between 2013 and 2023. Methods: A retrospective, cross-sectional study using publicly available data from the Brazilian Unified Health System’s Hospital Information System (SIH/SUS). We analyzed deaths among indigenous individuals in Pará from 2013 to 2023 attributed to lymphoid and hematopoietic malignancies. Variables included year of death, health macro-region, municipality, age group, ICD-10 neoplasm category, and indigenous race/ethnicity. Results: From 2013 to 2023, 16 deaths were recorded, with no entries for 2015. Mortality peaked in 2019 and 2021 (three deaths each), while 2014, 2016, and 2022 each had two deaths; all other years had one. Macro-regions I (Belém) and III (Santarém) accounted for 14 of 16 deaths (87.5%), and macro-region IV (Marabá) for the remaining two. By municipality, Belém reported four deaths and Oriximiná three; Afuá, Itaituba, Itupiranga, Jacareacanga, Mocajuba, Novo Progresso, Santa Bárbara do Pará, Santarém, and Tucuruí each reported one. Notably, 68.8% of deaths (11/16) occurred in individuals under 20 years, most frequently in the 10–14 age group (four deaths). Conclusion: Mortality from lymphoid and hematopoietic malignancies in Pará’s indigenous populations is predominantly among youth and concentrated in the Belém and Santarém regions. These findings underscore the need to strengthen epidemiological surveillance, improve early diagnostic and treatment access in remote areas, and tailor prevention strategies to the socio-cultural context of these communities. Limitations: small case count, potential underreporting, and lack of detailed clinical data.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
